-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 25, Hengrui Medicine stated that it had recently received the "Drug Registration Certificate" for irinotecan hydrochloride injection approved and issued by the State Drug Administration
.
This product is suitable for the treatment of patients with advanced colorectal cancer:
(1) Combine 5-fluorouracil and folinic acid to treat patients with advanced colorectal cancer who have not received chemotherapy in the past;
(2) As a single drug, it treats patients who have failed the 5-fluorouracil-containing chemotherapy regimen
.
Irinotecan hydrochloride injection was jointly developed by Japan’s Yakult, Fukushima Daiichi Pharmaceutical, Rona Planck and Pharmacia & Upjohn.
It was approved for the first time in the United States in June 1996 under the trade name Camptosar
.
Up to now, this product has been widely marketed and sold in many countries including China
.
After inquiries, the global sales of irinotecan injection in 2019 were approximately US$724 million, and sales data for 2020 have not yet been found
.
Up to now, irinotecan hydrochloride injection (2ml: 40mg) has invested about 6.
03 million yuan in research and development during the production reporting stage
